Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 19
- Publication type:
- Article
Works matching IS 21644403 AND DT 2023 AND VI 13 AND IP 1
Results: 15
1
2
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 19
- Publication type:
- Article
3
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic NSCLC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 18
- Publication type:
- Article
4
Imjudo, a New CTLA-4 Inhibitor, FDA Approved in Combination with Imfinzi for Unresectable HCC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 18
- Publication type:
- Article
5
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 17
- Publication type:
- Article
6
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, PlatinumResistant Ovarian Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 17
- Publication type:
- Article
7
Rezlidhia FDA Approved for Relapsed or Refractory AML with IDH1 Mutation.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 16
- Publication type:
- Article
8
Supportive Care and Management of Complications in BTCs: A Multidisciplinary Team Approach.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 15
- Publication type:
- Article
9
Survey Results Provide Insights into Biosimilar Use at Cancer Centers.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 11
- Publication type:
- Article
10
Ribociclib plus Endocrine Treatment Outperforms Chemotherapy in Advanced Breast Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 10
- By:
- Publication type:
- Article
11
Daily LMWH Not Beneficial in Pregnant Women with Inherited Thrombophilia and Recurrent Miscarriage.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 8
- Publication type:
- Article
12
Zanubrutinib Outperforms Ibrutinib in Relapsed or Refractory CLL/SLL.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 7
- By:
- Publication type:
- Article
13
Using Adaptive Leadership to Engage, Empower, and Energize.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 1
- By:
- Publication type:
- Article
14
Addition of Capivasertib to Fulvestrant Improves Outcomes in HR-Positive, HER2-Low or -Negative Metastatic Breast Cancer.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 1
- By:
- Publication type:
- Article
15
Restrictive Diet May Be Unnecessary in Patients Undergoing HSCT.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 1, p. 1
- By:
- Publication type:
- Article